APA (7th ed.) Citation

Ramos Perez, J. M., Patel, K. P., Loghavi, S., Garcia-Manero, G., Borthakur, G., Jabbour, E., . . . Konopleva, M. (2022). Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leukemia & Lymphoma, 63(3), 672. https://doi.org/10.1080/10428194.2021.1992757

Chicago Style (17th ed.) Citation

Ramos Perez, Jorge M., et al. "Value of Measurable Residual Disease Monitoring in Patients with Acute Promyelocytic Leukemia in the Era of Frontline 'Chemotherapy-free' Therapy." Leukemia & Lymphoma 63, no. 3 (2022): 672. https://doi.org/10.1080/10428194.2021.1992757.

MLA (9th ed.) Citation

Ramos Perez, Jorge M., et al. "Value of Measurable Residual Disease Monitoring in Patients with Acute Promyelocytic Leukemia in the Era of Frontline 'Chemotherapy-free' Therapy." Leukemia & Lymphoma, vol. 63, no. 3, 2022, p. 672, https://doi.org/10.1080/10428194.2021.1992757.